GEICAM Strengthens Leadership in Breast Cancer Research in Spain

The GEICAM Breast Cancer Research Group consolidates its leadership in oncology research in Spain, according to the results of the report by the Spanish Society of Medical Oncology (SEOM) on national cooperative groups, endorsed by the publication of its 2024 Annual Report, which compiles the milestones achieved by the organization and reinforces its role as a leading group in independent breast cancer research in Spain.

GEICAM’s leadership is particularly evident in the field of clinical trials and the number of participating patients. In SEOM’s analysis, the Group has conducted the most clinical trials in Spain (108 studies), a position reinforced by the data in the GEICAM 2024 Report, which includes a total of 172 scientific studies (including observational, epidemiological, and translational studies), reflecting its established research track record.

One in five patients in cancer trials in Spain comes from GEICAM

The scope of GEICAM’s research activity is evident in the participation of patients in its studies. According to the SEOM report, the Group accounts for nearly 20% of the patients included in oncology clinical trials in Spain, making it one of the organizations with the greatest contribution in this field. The GEICAM 2024 Report records the participation of more than 68,000 patients, a figure that reflects the magnitude and relevance of its contribution to oncology research.

GEICAM is also the cooperative group with the largest research network in Spain, with 959 partners and 201 associated centers and institutions, according to both the SEOM report and the Annual Report. This broad base of specialists and hospitals allows the Group to develop far-reaching cooperative and multidisciplinary research, ensuring the representativeness of the results obtained and their impact on clinical practice.

The intensity of GEICAM’s research activity is also reflected in its scientific output throughout its history. The 2024 Annual Report records a cumulative total of 232 publications in specialized journals and 508 conference presentations since the Group’s founding in 1995, a volume that demonstrates the continuity and solidity of its contribution to knowledge in breast cancer.

2024 Report: A Year of Progress

GEICAM closed 2024 with significant milestones in research and international outreach. The Annual Report highlights the promotion of pioneering projects in areas such as male breast cancer and pregnancy-associated breast cancer, as well as the presentation of results at world-renowned conferences such as ASCO, ESMO, and SABCS. It also includes new evidence on prevention and quality of life, with physical exercise programs in oncology and epidemiological studies on lifestyle habits and breast cancer.

The document also details the intense activity of its biobank, which at the end of the year stored 54,740 biological samples from 40,112 patients, consolidating its position as a key resource for translational research and precision medicine. This is in addition to the awarding of €298,000 in scholarships and grants for young clinicians, with the aim of further strengthening training and the future of breast cancer research in Spain.

Research needs society: “If you want, science can” campaign

In addition to its research activities, GEICAM develops awareness-raising, visibility-raising, and fundraising initiatives to promote research that reinforce its mission and expand the impact of science on society. Coinciding with World Breast Cancer Day , celebrated every October 19th, GEICAM emphasizes the importance of supporting research through the “If you want, science can” campaign, which this year focuses on the need to raise funds to finance new projects and raise awareness of the impact and increasing incidence of the disease in increasingly younger women.

The campaign, which includes real-life accounts from women diagnosed with breast cancer at early ages, as well as insights from oncologists and researchers, seeks to raise awareness about the value of science and the importance of gathering support to advance the diagnosis, treatment, and prevention of the disease.

__

(Featured image by Bermix Studio via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in GACETA MEDICA. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.